GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QUIA PHARMA AB (OSTO:QUIA) » Definitions » EV-to-FCF

QUIA PHARMA AB (OSTO:QUIA) EV-to-FCF : -3.83 (As of Apr. 08, 2025)


View and export this data going back to 2005. Start your Free Trial

What is QUIA PHARMA AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, QUIA PHARMA AB's Enterprise Value is kr38.91 Mil. QUIA PHARMA AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-10.17 Mil. Therefore, QUIA PHARMA AB's EV-to-FCF for today is -3.83.

The historical rank and industry rank for QUIA PHARMA AB's EV-to-FCF or its related term are showing as below:

OSTO:QUIA' s EV-to-FCF Range Over the Past 10 Years
Min: -11.13   Med: -1.82   Max: 14.99
Current: -4.09

During the past 13 years, the highest EV-to-FCF of QUIA PHARMA AB was 14.99. The lowest was -11.13. And the median was -1.82.

OSTO:QUIA's EV-to-FCF is ranked worse than
100% of 464 companies
in the Biotechnology industry
Industry Median: 2.275 vs OSTO:QUIA: -4.09

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-08), QUIA PHARMA AB's stock price is kr0.0082. QUIA PHARMA AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.023. Therefore, QUIA PHARMA AB's PE Ratio (TTM) for today is At Loss.


QUIA PHARMA AB EV-to-FCF Historical Data

The historical data trend for QUIA PHARMA AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QUIA PHARMA AB EV-to-FCF Chart

QUIA PHARMA AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.73 -2.04 -1.84 -0.73 -1.66

QUIA PHARMA AB Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -2.94 -0.73 - -1.66

Competitive Comparison of QUIA PHARMA AB's EV-to-FCF

For the Biotechnology subindustry, QUIA PHARMA AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QUIA PHARMA AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where QUIA PHARMA AB's EV-to-FCF falls into.


;
;

QUIA PHARMA AB EV-to-FCF Calculation

QUIA PHARMA AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=38.914/-10.172
=-3.83

QUIA PHARMA AB's current Enterprise Value is kr38.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. QUIA PHARMA AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-10.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


QUIA PHARMA AB  (OSTO:QUIA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

QUIA PHARMA AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0082/-0.023
=At Loss

QUIA PHARMA AB's share price for today is kr0.0082.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. QUIA PHARMA AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.023.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


QUIA PHARMA AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of QUIA PHARMA AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


QUIA PHARMA AB Business Description

Traded in Other Exchanges
Address
Virdings Alle 32 B, Uppsala, SWE, 754 50
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.

QUIA PHARMA AB Headlines

No Headlines